1. Home
  2. DECK vs NBIX Comparison

DECK vs NBIX Comparison

Compare DECK & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Deckers Outdoor Corporation

DECK

Deckers Outdoor Corporation

HOLD

Current Price

$101.64

Market Cap

14.2B

ML Signal

HOLD

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$179.94

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DECK
NBIX
Founded
1973
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Shoe Manufacturing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2B
13.2B
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
DECK
NBIX
Price
$101.64
$179.94
Analyst Decision
Buy
Strong Buy
Analyst Count
23
22
Target Price
$122.45
$180.91
AVG Volume (30 Days)
2.2M
1.1M
Earning Date
05-21-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
10.90
41.95
EPS
7.02
1.91
Revenue
$5,472,296,000.00
$161,626,000.00
Revenue This Year
$11.16
$24.73
Revenue Next Year
$6.96
$13.14
P/E Ratio
$13.92
$92.36
Revenue Growth
9.76
977.51
52 Week Low
$78.91
$122.14
52 Week High
$125.45
$181.18

Technical Indicators

Market Signals
Indicator
DECK
NBIX
Relative Strength Index (RSI) 47.20 64.49
Support Level $97.84 $153.96
Resistance Level $105.45 $181.18
Average True Range (ATR) 3.53 4.76
MACD -0.65 -0.14
Stochastic Oscillator 53.50 96.30

Price Performance

Historical Comparison
DECK
NBIX

About DECK Deckers Outdoor Corporation

Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Share on Social Networks: